Article
A substantial proportion of patients over age 65 years with newly diagnosed prostate cancer are not being treated according to existing guidelines for imaging in this setting.
New Drug Application initiated with FDA for TAR-200 for NMIBC
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
Hackensack University Medical Center Launches Educational Website for People with Kidney Cancer
FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer